Genetic Testing For Flt3, Npm1, And Cebpa Variants In Cytogenetically Normal Acute Myeloid Leukemia

Treatment of acute myeloid leukemia (AML) is based on risk stratification, primarily related to patient age and tumor cytogenetics. In patients with cytogenetically normal AML, the identification of variants in several genes, including FLT3, NPM1, and CEBPA, has been proposed to allow for further segregation in the management of this heterogeneous disease.